
|Articles|November 22, 2011
Poll: Do You Agree with the FDA's Decision to Pull Avastin?
Author(s)OBGYN.net Staff
This week the FDA pulled its accelerated approval of Avastin for women with HER2-negative metastatic breast cancer who have not undergone chemotherapy.
Advertisement
Everyone wants the best treatment available when it comes to cancer, breast cancer is no different. This week the FDA pulled its accelerated approval of Avastin for women with HER2-negative metastatic breast cancer who have not undergone chemotherapy. Avastin is still available for other types of cancer but because it is no longer approved for breast cancer insurance companies will not cover the approximately $8000.00 per month it costs. This puts breast cancer treatment out of reach for many women who say this was working for them.
Advertisement
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Diagnosing PMOS in adolescents
2
ACOG's 2026-27 respiratory virus immunization recommendations in pregnancy, postpartum
3
FDA working with manufacturers to increase access to estradiol transdermal patches
4
From PCOS to PMOS: A welcome and more inclusive name
5




